Matches in Wikidata for { <http://www.wikidata.org/entity/Q92415695> ?p ?o ?g. }
Showing items 1 to 64 of
64
with 100 items per page.
- Q92415695 description "article scientifique publié en 2020" @default.
- Q92415695 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q92415695 description "scientific article published on 02 January 2020" @default.
- Q92415695 description "wetenschappelijk artikel" @default.
- Q92415695 description "наукова стаття, опублікована 2 січня 2020" @default.
- Q92415695 name "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 name "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 type Item @default.
- Q92415695 label "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 label "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 prefLabel "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 prefLabel "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 P1433 Q92415695-252066DC-3E27-4E50-87DE-0426E828DC5D @default.
- Q92415695 P1476 Q92415695-98A8CC3C-12C4-4537-A0BA-695CF914B5B2 @default.
- Q92415695 P2093 Q92415695-094BCC37-CD14-4CDA-88B0-C95C6D95269C @default.
- Q92415695 P2093 Q92415695-1DA60DF0-42DE-4233-A832-00E781C69D9C @default.
- Q92415695 P2093 Q92415695-248FF490-83F9-4B8F-8E4E-3B00637B0321 @default.
- Q92415695 P2093 Q92415695-3354187A-3BCD-443E-A6D4-B2F5A12FAF7D @default.
- Q92415695 P2093 Q92415695-6477F900-9661-45AB-B634-8788CEADA7CC @default.
- Q92415695 P2093 Q92415695-73EC76FB-5CCD-42EA-909F-4E868C4BA496 @default.
- Q92415695 P2093 Q92415695-786C43C4-0261-4DE2-93B9-681EC7D1EBB7 @default.
- Q92415695 P2093 Q92415695-A9318F26-B7AE-4B5F-9940-101BDE74FBF7 @default.
- Q92415695 P2093 Q92415695-A94C75F9-1807-4B50-BE53-47992B80BE8C @default.
- Q92415695 P2093 Q92415695-B5CEA2EF-72B7-4962-B834-D200E2FD9057 @default.
- Q92415695 P2093 Q92415695-E09DE7DF-7F4A-4F26-B40C-D9D818AF49D6 @default.
- Q92415695 P2093 Q92415695-F6886848-287C-469A-B804-6BC823914DC8 @default.
- Q92415695 P2093 Q92415695-FD79A1C8-B396-4B9A-9ECA-63B2A379782B @default.
- Q92415695 P304 Q92415695-DA8964CE-40B1-440A-9F67-C4A39070AE66 @default.
- Q92415695 P31 Q92415695-7959EF7B-3A9B-427B-8DEB-42B78C4F0B10 @default.
- Q92415695 P356 Q92415695-E5942A7D-F065-472C-BF5D-7CC8FD88E6F9 @default.
- Q92415695 P478 Q92415695-FADF9ABA-AE1D-4035-8599-00CC582BD3C9 @default.
- Q92415695 P50 Q92415695-5194384E-D7FE-48A5-B290-EB989350C240 @default.
- Q92415695 P50 Q92415695-695A94CA-0AB8-42DE-96A1-0E00A0265202 @default.
- Q92415695 P50 Q92415695-6F70E06A-845C-4897-9E99-9BD2D294127E @default.
- Q92415695 P577 Q92415695-7C794E8F-5560-4BA1-A71B-AB8BDD5533C8 @default.
- Q92415695 P698 Q92415695-15AEA131-F694-44BC-8067-647BBEF01E1C @default.
- Q92415695 P921 Q92415695-9BE0D6CF-E2BB-4E98-B4FD-1A0005BA0159 @default.
- Q92415695 P356 J.EJCA.2019.11.016 @default.
- Q92415695 P698 31901705 @default.
- Q92415695 P1433 Q332260 @default.
- Q92415695 P1476 "Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma" @default.
- Q92415695 P2093 "Ana Arance" @default.
- Q92415695 P2093 "Ashwin Gollerkeri" @default.
- Q92415695 P2093 "Carmen Loquai" @default.
- Q92415695 P2093 "Caroline Robert" @default.
- Q92415695 P2093 "Claus Garbe" @default.
- Q92415695 P2093 "Gabriella Liszkay" @default.
- Q92415695 P2093 "Helen J Gogas" @default.
- Q92415695 P2093 "Ivana Krajsova" @default.
- Q92415695 P2093 "Jan Willem B de Groot" @default.
- Q92415695 P2093 "Keith T Flaherty" @default.
- Q92415695 P2093 "Mario Mandala" @default.
- Q92415695 P2093 "Michael D Pickard" @default.
- Q92415695 P2093 "Ralf Gutzmer" @default.
- Q92415695 P304 "33-44" @default.
- Q92415695 P31 Q13442814 @default.
- Q92415695 P356 "10.1016/J.EJCA.2019.11.016" @default.
- Q92415695 P478 "126" @default.
- Q92415695 P50 Q32649390 @default.
- Q92415695 P50 Q32650033 @default.
- Q92415695 P50 Q89457677 @default.
- Q92415695 P577 "2020-01-02T00:00:00Z" @default.
- Q92415695 P698 "31901705" @default.
- Q92415695 P921 Q42824827 @default.